SLC31A1 and cancer: The resistance to cisplatin due to decreased uptake is considered as a key limitation of cisplatin treatment, while CTR1 plays an important role in the development of resistance to cisplatin, leading to the ineffectiveness of the treatment of cancer [131,132].